コンテンツへスキップ
Merck
  • On the generalized valence bond description of the anomeric and exo-anomeric effects: an ab initio conformational study of 2-methoxytetrahydropyran.

On the generalized valence bond description of the anomeric and exo-anomeric effects: an ab initio conformational study of 2-methoxytetrahydropyran.

Carbohydrate research (2005-08-02)
Rodrigo S Bitzer, André G H Barbosa, Clarissa O da Silva, Marco A C Nascimento
要旨

An ab initio conformational study of the alpha- and beta-glycosidic C1-O1 bonds has been carried out on the axial and equatorial forms of 2-methoxytetrahydropyran (2-MTHP) at the HF/6-31G(d,p) and GVB-PP/6-31G(d,p) levels of calculation. Six conformers of 2-MTHP were fully optimized at both levels. The calculations have shown that the conformer containing the (+sc) orientation around the axial C1-O1 bond is the most stable one and is favored over that bearing the (-sc) arrangement about the equatorial C1-O1 bond by 1.39 (HF) and 1.52 (GVB-PP)kcal/mol. The potential energy surfaces for rotating about the axial and equatorial C1-O1 bonds were constructed at the HF and GVB-PP levels. For each form of 2-MTHP the HF and GVB-PP potential curves exhibit similar profiles. This shows that both methods provide similar descriptions for the position of the conformational minima and for the values and location of the rotational barriers. In addition to the conformational study, a discussion concerning the nature of the chemical bond in acetal fragments and the origin of the anomeric and exo-anomeric effects is presented in terms of optimized non-orthogonal GVB orbitals of 2-MTHP. The intramolecular factors that respond for the order of stability and conformational changes in bond lengths of the conformers of 2-MTHP are examined in light of the GVB description. The problems associated with the use of the NBOs (natural bond orbitals) to analyze chemical bonding in the acetal fragments are discussed, and the choice for the GVB-PP description is justified.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
2-メトキシテトラヒドロピラン, 98%